Article Details

Brugada syndrome (BrS) is an inherited cardiac channelopathy associated with characteristic electrocardiographic (ECG) changes and an increased risk of sudden cardiac death (SCD). These ECG findings are often concealed and may be unmasked by sodium channel blocking agents. Lithium, a first-line mood stabilizer for bipolar disorder, exerts clinically relevant cardiac sodium channel blockade, though its association with BrS is infrequently reported. We describe a case of a 28-year-old male with bipolar disorder type I who presented with chest pain and was found to have a type 1 Brugada ECG pattern while taking lithium therapy. Following discontinuation of lithium and transition to aripiprazole, repeat ECG one year later demonstrated resolution of the Brugada pattern. Given lithium’s widespread use and the transient nature of drug-induced Brugada patterns, heightened clinical awareness is essential to avoid misdiagnosis and mitigate arrhythmic risk.